ICL

Prezzo ICL Group Ltd (ADRs)

Closed
ICL
$5,44
-$0,05(-0,91%)

*Data last updated: 2026-05-04 04:44 (UTC+8)

As of 2026-05-04 04:44, ICL Group Ltd (ADRs) (ICL) is priced at $5,44, with a total market cap of $7,02B, a P/E ratio of 32,60, and a dividend yield of 2,80%. Today, the stock price fluctuated between $5,43 and $5,53. The current price is 0,18% above the day's low and 1,62% below the day's high, with a trading volume of 549,39K. Over the past 52 weeks, ICL has traded between $5,08 to $5,67, and the current price is -4,05% away from the 52-week high.

ICL Key Stats

Yesterday's Close$5,49
Market Cap$7,02B
Volume549,39K
P/E Ratio32,60
Dividend Yield (TTM)2,80%
Dividend Amount$0,04
Diluted EPS (TTM)0,17
Net Income (FY)$226,00M
Revenue (FY)$7,15B
Earnings Date2026-05-13
EPS Estimate0,10
Revenue Estimate$1,92B
Shares Outstanding1,27B
Beta (1Y)0.938
Ex-Dividend Date2026-03-10
Dividend Payment Date2026-03-25

About ICL

ICL Group Ltd, together with its subsidiaries, operates as a specialty minerals and chemicals company worldwide. It operates in four segments: Industrial Products, Potash, Phosphate Solutions, and Innovative Ag Solutions (IAS). The Industrial Products segment produces bromine out of a solution that is a by-product of the potash production process, as well as bromine-based compounds; produces various grades of potash, salt, magnesium chloride, and magnesia products; and produces and markets phosphorous-based flame retardants and other phosphorus-based products. The Potash segment extracts potash from the Dead Sea; mines and produces potash and salt; produces Polysulphate; produces, markets, and sells magnesium and magnesium alloys, as well as related by-products, including chlorine and sylvinite; and sells salt. The Phosphate Solutions segment uses phosphate commodity products to produce specialty products; produces and markets phosphate-based fertilizers, as well as sulphuric acid, green phosphoric acid, and phosphate fertilizers; and manufactures thermal phosphoric acid for various industrial end markets, such as oral care, cleaning products, paints and coatings, water treatment, asphalt modification, construction, and metal treatment. It also develops and produces functional food ingredients and phosphate additives for use in the processed meat, poultry, seafood, dairy, beverage, and baked goods markets; and produces milk and whey proteins for the food ingredients industry. The IAS segment develops, manufactures, markets, and sells fertilizers based primarily on nitrogen, potash, and phosphate, including water soluble specialty, liquid, soluble, and controlled-release fertilizers. It sells its products through marketing companies, agents, and distributors. The company was formerly known as Israel Chemicals Ltd. and changed its name to ICL Group Ltd in May 2020. The company was founded in 1968 and is headquartered in Tel Aviv, Israel.
SectorBasic Materials
IndustryAgricultural Inputs
CEOElad Aharonson
HeadquartersTel Aviv,None,IL

ICL Group Ltd (ADRs) (ICL) FAQ

What's the stock price of ICL Group Ltd (ADRs) (ICL) today?

x
ICL Group Ltd (ADRs) (ICL) is currently trading at $5,44, with a 24h change of -0,91%. The 52-week trading range is $5,08–$5,67.

What are the 52-week high and low prices for ICL Group Ltd (ADRs) (ICL)?

x

What is the price-to-earnings (P/E) ratio of ICL Group Ltd (ADRs) (ICL)? What does it indicate?

x

What is the market cap of ICL Group Ltd (ADRs) (ICL)?

x

What is the most recent quarterly earnings per share (EPS) for ICL Group Ltd (ADRs) (ICL)?

x

Should you buy or sell ICL Group Ltd (ADRs) (ICL) now?

x

What factors can affect the stock price of ICL Group Ltd (ADRs) (ICL)?

x

How to buy ICL Group Ltd (ADRs) (ICL) stock?

x

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.

Other Trading Markets

ICL Group Ltd (ADRs) (ICL) Latest News

2025-06-17 05:43

ICL确认与朝鲜关联个人曾贡献于Cosmos代码库 其代码已移除且无遗留风险

Gate News bot 消息,Interchain Labs(ICL)已确认,一名后来被确认与朝鲜有关联的个人在 2022 年至 2024 年期间受雇于前维护人员期间,曾为 Cosmos 代码库做出贡献。 这位 Cosmos 核心开发人员与安全联盟 (Security Alliance) 和 Asymmetric Research 合作发布了一份安全报告,证实该个人对两个代码库的访问权限有限:cosmos/IAVL 和 cosmos/cosmos-sdk。审查发现,在 SDK v2 取消后,他贡献的大部分代码已被弃用或从路线图中移除,独立审计未发现任何剩余风险或漏洞。 然而,为了提高透明度,ICL 将在下个月在 Cosmos HackerOne 页面上提供双倍赏金,奖励发现与该参与者的 GitHub 帐户“cool-develope”相关的任何符合条件的漏洞的人员。 具体而言,该个人从 2022 年年中到 2024 年 11 月,在 ICL 成立和 Cosmos 第三方维护模式结束之前,曾为前核心堆栈维护供应商工作。ICL 在一份声明中表示,在接管所有核心堆栈开发后,团队实施了新的安全和招聘协议,从而发现了这个问题,并阻止其进一步的贡献。同一人后来再次申请职位,但被标记并被拒绝。 ICL 表示,自 2 月份以来,它已对所有核心 Cosmos 存储库实施了全面的安全升级,包括撤销旧访问权限、重新许可所有贡献者、轮换凭证以及加强审计控制。 消息来源:The Block

Hot Posts su ICL Group Ltd (ADRs) (ICL)

MEV_Whisperer

MEV_Whisperer

04-30 15:13
Just caught wind of some interesting news coming out of the vision correction space. STAAR Surgical got FDA clearance to expand the age range for its EVO Visian ICL procedure - that's the Implantable Collamer Lens for those wondering what icl meaning refers to in medical device circles. They're now approved to treat patients up to age 60 instead of just 45. Pretty significant move. What caught my attention is the underlying data. The approval is backed by three years of FDA clinical trial results from 629 eyes, showing a solid safety profile. We're talking 1.25 safety index at year three, zero cases of pupillary block or pigment dispersion, and only a 0.16% rate of anterior subcapsular cataracts. Those are the kinds of numbers that get surgeons comfortable recommending a procedure. Here's where it gets interesting from a market perspective. Real-world adoption data from 19 US refractive practices shows EVO ICL being used in over 70% of procedures for high myopia cases (patients with -8.0 diopters and above). Meanwhile, laser-based LASIK procedures have tanked - down nearly 40% over the past three years. Patient surveys show 53% of US vision correction consumers are now looking at alternatives to LASIK. The numbers suggest there's a real shift happening. Management estimates 24 million myopic adults in the US could be candidates, including 8 million in that newly approved 46-60 age bracket. In international markets where the 46-60 segment has been available longer, it represents about 6% of their total EVO ICL patient base. Stock-wise, STAA popped 8.4% on the announcement. Over six months though, it's down 37.2%, which puts it underwater against both the broader medical industry and the S&P 500. Current market cap is sitting around $805.82 million. The long-term case seems solid though - as LASIK demand continues declining and more patients opt for lens-based alternatives like ICL procedures, volumes should keep climbing. One other note: the company recently appointed Warren Foust and Deborah Andrews as interim co-CEOs effective February 1st while the board searches for a permanent CEO. That's worth keeping an eye on as leadership transitions tend to create some uncertainty. The broader intraocular lens market is valued around $5.34 billion as of 2026 with expected 4.72% annual growth through 2035, so there's real market expansion happening here. Worth monitoring if you follow the medical device space.
0
0
0
0
BearMarketBard

BearMarketBard

04-30 14:37
Just caught something interesting about the vision correction market that's worth paying attention to. STAAR Surgical got FDA approval to expand the age indication for their EVO implantable collamer lenses—basically, ICL meaning these are permanent lens implants that sit inside your eye to correct myopia. The approval extends eligibility from the previous 21-45 age range all the way to 60 years old, which is a pretty significant move. What caught my eye is the data backing this. Three-year FDA trial results covering 629 eyes showed a solid safety profile—1.25 safety index with virtually zero cases of pupillary block or pigment dispersion. The cataract incidence was minimal at 0.16%. Real-world adoption data is even more telling: surgeons are using EVO ICL in over 70% of procedures for patients with high myopia (-8.0 diopters and above), which suggests a major shift away from laser-based LASIK procedures. The market context makes this even more interesting. LASIK volumes have cratered nearly 40% over three years, hitting multi-decade lows. Meanwhile, 53% of U.S. vision correction consumers are now actively considering alternatives to LASIK. Management estimates there are 24 million myopic adults in the U.S. who could be candidates, with 8 million specifically in that newly approved 46-60 age segment. That's a massive addressable market that was previously locked out. From an investment angle, this positions STAA well in a growing sector. The broader intraocular lens market is valued at $5.34 billion in 2026 and expected to grow at 4.72% CAGR through 2035. With declining LASIK demand and strong surgeon preference for lens-based solutions, the expanded age indication should drive meaningful volume growth. The stock already popped 8.4% since the announcement, though it's still down 37.2% over six months while the S&P 500 gained 8.8%. One thing to note: the company recently appointed Warren Foust and Deborah Andrews as interim co-CEOs effective February 2026, so there's some leadership transition happening in the background while they search for a permanent CEO. Current market cap is around $805.82 million. The reversible nature of ICL procedures—preserving natural corneal tissue and the crystalline lens—appeals to a lot of patients looking for flexible long-term vision strategies. Combined with the safety data and the expanding addressable market, this approval could be a meaningful catalyst for the refractive surgery space. Worth monitoring if you're tracking the medical device sector.
0
0
0
0
GateUser-bd883c58

GateUser-bd883c58

04-24 06:07
本报(chinatimes.net.cn)记者何一华 李未来 北京报道 霍尔木兹海峡通航危机除了导致国际原油价格大涨,也让非常小众的化工产品价格出现大幅波动。 今年以来溴素价格稳中上行,进入3月后,溴素价格走势坐上了火箭。生意社数据显示,3月8日溴素报价还是39700元/吨,到了3月22日,价格已经飙升至51000元/吨,4月3日,溴素报价已经变更为70200元/吨。 资本市场自然不会错过这轮行情,溴素概念股频频拉升,截至4月3日收盘,苏利股份(603585.SH)6天3板,山东海化(000822.SZ)、鲁北化工(600727.SH)等涨幅靠前。 记者注意到,溴素作为小众化学产品产能较小,并不是上市公司的主营业务,溴素价格涨价又能否带动相关公司业绩增长? 滨化股份(601678.SH)董秘办工作人员告诉《华夏时报》记者,公司溴素产能为5000多吨,营收占比低,但是单价大幅波动时仍会对公司业绩产生一定影响。另外一家上市公司工作人员则表示,对小公司来说增加几千万利润还不错,但是对大公司来说业绩提升作用有限。 **海外供应受阻** 2026年1—3月,国内卤水溴素生产企业停产限产,海水溴素企业受气温偏低影响,开工负荷处于低位,生产企业库存压力不大,持货方低价惜售,市场价格稳中上行。 生意社数据显示,2026年1月3日,溴素报价为35000元/吨,到了1月20日,报价变为38600元/吨,2月6日,溴素报价升至41600元/吨,此后溴素报价趋于平稳,2月23日报价仍为41600元/吨,并于3月4日回落至39700元/吨。此后溴素价格一路上涨至4月3日的70200元/吨。 卓创资讯溴素分析师赵倩倩告诉《华夏时报》记者,3月以来溴素市场价格上涨主要是供应面驱动,国内溴素生产企业产量逐渐提升,受中东地缘局势影响,国外溴素货源供应减少,船运周期延长,进口货源无法及时供应,国内总供应量减少,卖方捂盘惜售,报盘探涨情绪持续浓厚,市场价格强势上行。 银河证券指出,中东地区地缘冲突升级,一方面不排除以色列部分溴素生产装置阶段性降负或停产进而导致溴素出现供应缺口的可能;另一方面,以色列、约旦溴素出口的物流成本将显著上涨,溴素运输周期也存在较大不确定性,溴素价格中枢有望随之抬升。 据悉,以色列和约旦是全球两大溴素主产国。隆众资讯数据,以色列、约旦溴素产能在全球占比分别为33%、19%。我国是全球最大的溴素消费国,但溴素进口依赖度较高,以色列、约旦是我国最主要的溴素进口国。海关总署数据,2025年我国分别自以色列、约旦进口溴素3.5、1.4万吨,合计约占总进口量的64.7%。 赵倩倩向记者解释,全球溴素行业集中度较高,其中以色列、约旦、美国合计产能占全球总产能的60%以上,中国产能约15万吨左右。以色列、约旦依托死海周边丰富的卤水资源优势,死海卤水中溴素含量高,产能约占全球总产能的40%。 记者了解到,2026年1月和2月溴素价格的上涨也和海外产能有关。根据有关报道,全球最大生产商以色列化工(ICL)自2025年以来便减少了溴素出口,转而提升其下游溴化物产品产量。 中国另外一个溴素进口大国则遭遇意外天灾。1月21日,约旦南部遭遇大雨引发洪水,导致全球第二大溴素生产基地约旦溴业公司(JBC)的供应中断。该公司年产10万吨溴素,占全球总产能的13%—14%。 **产能将逐步回升** 记者注意到,虽然价格出现大涨,但是溴素总体产能较小,在上市公司中营收占比较低。 亚钾国际2025年半年报显示,公司参股的亚洲溴业拥有2.5万吨/年的溴素产能装置,2025年力争进一步扩建至5万吨/年,但其氯化钾收入34.64亿元,占比达到97.65%;卤水收入4722万元,占比1.33%;其他收入3631万元,占比1.02%。 山东海化作为国内地下卤水提溴龙头,产能在1万吨左右,2025年营业收入为47.45亿元,溴素营收仅有2.007亿元,占比4.23%;鲁北化工溴素产能在5000吨左右,2025年溴素产量为3245吨,销量为3117吨。公司2025年营收整体为50.89亿元,溴素营收为7381万元,不过毛利率比较高,达到52.91%。 鲁北化工董秘办工作人员告诉记者,毛利率高一方面是生产成本相对较低,另一方面销售价格较高;价格高源于下游需求稳健,供给端难以快速跟上。“溴素下游主要用于溴系阻燃剂、制药等领域,需求稳定。” 该工作人员进一步表示,溴素生产以海水提溴、地下卤水提溴、矿岩提溴为主,海水提溴受溴素浓度影响,仅渤海沿岸等特定沿海区域可开展,南方沿海多不具备条件。而地下卤水开采受国家严控,也无法无限制开采。 对于近期溴素价格上涨,该工作人员坦言,3月以来上涨中东冲突物流运输受限,进口受阻导致国内短期供应紧张有关。但也有季节性因素,“冬季溴素蒸发浓度不足,多处于停产状态,产量小,每年该时段价格均会有所上涨,‘五一’后产量逐渐回升,价格或逐步回落。” 赵倩倩也给出类似的观点。“随着气温回升推动场内海水溴素产量增加,带动行业开工率进一步提升,国内市场溴素供应逐渐增加,前期受环保检查停产企业,4月份或有陆续复工可能,多关注恢复生产后产量情况。” 此外,赵倩倩认为,4月份需持续关注下游用户接货心态,高端价格向下传导仍需时间,若传导尚可,对市场为利好驱动,若传导不畅,市场价格或高位回调,然具体拐点出现在哪一时刻,还需持续关注。 至于溴素价格对下游的影响,赵倩倩表示,溴素价格上涨导致下游生产企业成本压力较大,部分产品跟随溴素价格上涨,然高端价格向下传导困难,买方多谨慎观望,视订单生产情况刚需采购。 责任编辑:李未来 主编:张豫宁
0
0
0
0